Login
Companies $WST
$417.41 +$0.99 (0.24%) Live
WEST PHARMACEUTICAL SERVICES INC logo

WEST PHARMACEUTICAL SERVICES INC

westpharma.com

What Do They Do?

Sells packaging and delivery systems for injectable drugs to drugmakers. Also designs and assembles custom devices for diagnostic and medical-device companies.

How Do They Make Money?

Customers buy proprietary products, with sales counted when products ship or are delivered. Sales of contract-manufactured products, some proprietary products, and development and tooling work are counted as West performs the work.

revenue
SegmentShareRevenue
Proprietary Products
Sold outright

81%
FY2022: 83%
Contract-Manufactured Products
Recurring

19%
FY2022: 17%

Who Are Their Customers?

Drugmakers buy packaging and delivery products; diagnostic and medical-device companies buy custom-made components and devices. West sells mainly through its own sales force and distribution network, with limited use of sales agents and regional distributors.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2024: 12% from one customer

Do Revenues Turn Into Profits?

Yes. It kept 16 cents of every revenue dollar as net income in FY2025 and turned 15 cents into free cash flow.

Operating income, FY2025
19% of revenue
▲ +3% vs FY2024 ($569.9M, 20%)
Net income, FY2025
16% of revenue
▲ 0% vs FY2024 ($492.7M, 17%)
Free cash flow, FY2025
15% of revenue
▲ +70% vs FY2024 ($276.4M, 10%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +9%
vs $804.6M in Q3 FY2025
Net income
▲ +53%
vs $140M in Q3 FY2025
Proprietary Products share of revenue vs 80.5% in Q3 FY2025
  • Jul 23, 2026 Raised full-year 2026 sales and adjusted earnings guidance Raised its expected full-year net sales and adjusted earnings per share ranges.
  • Jul 14, 2026 Signed updated technology-sharing and distribution agreements with Daikyo The agreements cover product technology and distribution, with 10-year terms.
  • Jun 1, 2026 Named Michel Lagarde chief executive; Eric Green will leave and Robert Friel become chair Lagarde's appointment takes effect August 31, when Green leaves the board and Friel becomes chair.
  • May 11, 2026 Cyberattack disrupted global operations Core systems were restored, while shipping, receiving and manufacturing at some sites were still being restored.

Growing. Revenue grew 9% in 4 years, from $2.8B in FY2021 to $3.1B in FY2025, about 2% a year.

Revenue over time
Proprietary Products Contract-Manufactured Products
$5B$2.5B$0

Who Do They Compete With?

Competes with Datwyler, Aptar, SMC, Phillips Medisize, Sharp, and PCI Pharma Services

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support